Prostate-Cancer Mortality at 11 Years of Follow-up
Author(s) -
Fritz H. Schröder,
Jonas Hugosson,
Monique J. Roobol,
Teuvo L.J. Tammela,
Stefano Ciatto,
Vera Nelen,
Maciej Kwiatkowski,
M. Luján,
Hans Lilja,
Marco Zappa,
Louis Denis,
Franz Recker,
Álvaro Páez,
Liisa Määttänen,
Chris H. Bangma,
Gunnar Aus,
Sigrid Carlsson,
Arnauld Villers,
Xavier Rébillard,
Theodorus van der Kwast,
Paula Kujala,
B. G. Blijenberg,
UlfHåkan Stenman,
Andreas Huber,
Kimmo Taari,
M Hakama,
Sue Moss,
Harry J. de Koning,
Anssi Auvinen
Publication year - 2012
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1113135
Subject(s) - prostate cancer , medicine , oncology , prostate specific antigen , cancer , prostate , randomized controlled trial
Several trials evaluating the effect of prostate-specific antigen (PSA) testing on prostate-cancer mortality have shown conflicting results. We updated prostate-cancer mortality in the European Randomized Study of Screening for Prostate Cancer with 2 additional years of follow-up.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom